Research Programs and Clinical Trials

Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) for the Treatment of Fabry Disease

Safety and Efficacy Study of Several Replagal Dosing Regimens on Cardiac Function in Adults With Fabry Disease

GCO# 03-1256, Evaluation of a Web-based, Multi-media Tutorial for Fabry Disease

Pulmonary Disease and Exercise Tolerance in Boys with Fabry Disease

Replagal Treatment IND Site Update


Clinical Trials

Children & Clinical Studies